title: Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.
abstract: BACKGROUND
  Sweet's syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease.
  
  
  OBJECTIVE
  Proton pump inhibitor-associated Sweet's syndrome is described in a woman with recurrent breast cancer.
  
  
  METHODS
  PubMed was used to search the following terms, separately and in combination: acute febrile neutrophilic dermatosis, breast cancer, malignancy, paraneoplastic, proton pump inhibitor, and Sweet's syndrome. All papers were reviewed and relevant manuscripts, along with their reference citations, were evaluated.
  
  
  RESULTS
  Proton pump inhibitors have previously been associated with cutaneous adverse reactions including maculopapular rash, subacute cutaneous lupus erythematosus and toxic epidermal necrolysis. However, drug-induced Sweet's syndrome has not been observed in patients receiving proton pump inhibitors. The reported woman developed Sweet's syndrome after initial exposure and subsequent repeat challenge to proton pump inhibitors; subsequent studies also observed recurrence of her breast cancer presenting as metastases to her stomach and bone.
  
  
  CONCLUSIONS
  Drug-induced Sweet's syndrome has most commonly been associated with granulocyte colony stimulating factor in oncology patients. Malignancy-associated Sweet's syndrome has been observed in patients with solid tumors, including breast cancer. Confirmation of proton pump inhibitor-induced Sweet's syndrome, by repeat challenge with another medication in the same class of drug, was observed in a woman with breast cancer; although the subsequent discovery of recurrent breast cancer presenting as gastric mucosa and vertebral metastases also raises the possibility of concurrent paraneoplastic Sweet's syndrome, her Sweet's syndrome symptoms and lesions resolved without recurrence while her recurrent metastatic visceral malignancy persisted. In summary, medication-associated Sweet's syndrome can occur in oncology patients and proton pump inhibitors should be added to the list of medications associated with the potential to cause drug-induced Sweet's syndrome.
authors.affiliation: Department of Dermatology, University of California San Diego, San Diego, CA, USA.
authors.forename: Philip R
authors.initials: PR
authors.lastname: Cohen
keywords: Sweet; acute; breast; cancer; dermatosis; esomeprazole; febrile; inhibitor; neutrophilic; omeprazole; proton; pump; syndrome